Fisher & Paykel Healthcare Corporation Limited today announced its results for the half year ended 30 September 2016. Net profit after tax was up 26% for the half at a record NZ$78.2 million.
Read more
Fisher & Paykel Healthcare Corporation Limited today announced a record profit from continuing operations of NZ$72.9 million after-tax for the financial year ended 31 March 2003. Revenue for the year grew 15%, in US dollar terms, compared with the prior year.
Fisher & Paykel Healthcare Corporation Limited announced today that very strong growth in its respiratory and acute care product group contributed to profit after tax of NZ$28.3 million for the six months ended 30 September 2008, a 51% increase on the same peri...
Fisher & Paykel Healthcare Corporation Limited announced today that continuing strong volume growth in its obstructive sleep apnea (OSA), respiratory and acute care products contributed to operating revenue of NZ$172.5 million or US$127.7 million for six months en...
Fisher & Paykel Healthcare Corporation Limited today reported record trading revenue of NZ$173.2 million for the six months ended 30 September 2006, up 28% against the prior comparable period.
Fisher & Paykel Healthcare Corporation Limited announced today that ongoing growth from new products has contributed to record operating profit and a higher interim dividend.
Fisher & Paykel Healthcare Corporation Limited announced today that 42% OSA product group revenue growth, in US dollar terms, contributed to a 14% increase in first half operating profit to a record NZ$47.4 million.
Fisher & Paykel Healthcare Corporation Limited today announced a record profit of NZ$37.0 million for the six months ended 30 September 2009, 31% above the prior comparable period.
Revenue growth from new products contributed to Fisher & Paykel Healthcare Corporation Limited’s record first half revenue of NZ$104.9 million and an increased operating profit of NZ$37.0 million for the six months ended 30 September 2003.
Fisher & Paykel Healthcare Corporation Limited today announced record revenue for the year ended 31 March 2005 and a 14% increase in operating profit to NZ$89.7 million.
Find clinical evidence and practice guidelines for delivering nasal high flow (aka HFNC) therapy.
The heating and humidifying of respiratory gases is crucial for intubated patients. Learn about humidification devices, including active and passive.
Featuring under nose NIV masks (F&P Visairo) and full face NIV masks - (F&P Nivairo), with vented and non-vented options to suit your hospital NIV mask needs.
Establish effective spontaneous breathing or assist ventilation of the lungs
Respiratory support that replaces spontaneous breathing
Noninvasive respiratory support that provides a continuous distending pressure
Noninvasive respiratory support that delivers high flows of blended air and oxygen
Designed to work in harmony with the way patients naturally breathe while they sleep
F&P SleepStyle - designed to strike the balance between comfort and effective treatment
The AIRVO 2 family enables the transition of Optiflow therapy across critical, non-critical areas of the hospital and into the home.
Humidification for patients using a mask at home
Humidification for patients with a tracheostomy at home
Our newest Airvo features an integrated battery, high-pressure oxygen input and a broader flow range.
Optiflow nasal high flow therapy explained, what is it and how does it work?
F&P Solo™ Nasal is the world’s first AutoFit™ mask. It simplifies setup like no other, using AutoLock™ technology - stretch to fit, touch to adjust.
Airvo, F&P 950 and F&P 850 – this trio of humidification and respiratory support devices facilitate multiple respiratory therapies across the hospital
Join our global team. View and apply for jobs with us.
Get in touch with our team, find a distributor or send an enquire.
We value your privacy. Our websites and applications use cookies to function properly and securely.